Android app on Google Play

Morning Movers 06/18: (JRJC) (GBG) (ELT) (BVSN) Higher; (BODY) (INFI) (DSW) Lower

June 18, 2012 10:27 AM EDT Send to a Friend
Body Central Corp. (Nasdaq: BODY) 47.4% LOWER; sees Q2 net revenues in the range of $77 million to $79 million, comparable sales to decrease in a range of 7 to 9 percent and diluted earnings per share in the range of $0.19 to $0.21, based on diluted weighted-average shares outstanding of 16.4 million. Body Central previously saw EPS of $0.26 - $0.28 and sales of $80 - $82 million. The Street sees sales of $82 million and EPS of $0.27. Sees FY12 net revenues in the range of $323 million to $328 million, comparable sales to decrease in a range of 4 to 6 percent and diluted earnings per share in the range of $1.07 to $1.11, based on diluted weighted-average shares outstanding of 16.4 million. The Company previously expected EPS of $1.34 - $1.38 and sales of $333 - $337 million. The Street is looking for EPS of $1.35 and sales of $335.4 million.

China Finance Online Co. Limited (Nasdaq: JRJC) 32.2% HIGHER; the company announced that its flagship portal site Stockstar.com has entered into an exclusive partnership with Baidu.com (Nasdaq: BIDU) on a mobile web application to provide financial information services.

Great Basin Gold (AMEX: GBG) 16% HIGHER; shares plunged very sharply just ahead of the close on Friday. The stock has taken back all that loss this morning. Not hearing any company-specific news.

Elster Group SE (NYSE: ELT) 15.9% HIGHER; the company confirmed that it is in discussions with Melrose PLC regarding a potential cash offer for all outstanding shares of Elster at US$20.50 per ADS, or approximately US$2.3 billion in aggregate on a fully diluted basis.

Infinity Pharmaceuticals, Inc. (Nasdaq: INFI) 11.3% LOWER; announced interim data from its Phase 2, double-blind, randomized, placebo-controlled study of saridegib (IPI-926) in patients with metastatic or locally advanced, inoperable chondrosarcoma. The primary endpoint of the Phase 2 study was progression-free survival. While the final analysis is not complete, a planned futility analysis of data from the study was conducted by the study’s independent Data Monitoring Committee and concluded that treatment with saridegib was similar to placebo and, therefore, the trial would not meet its primary endpoint. In the trial, saridegib was generally well tolerated. Based on this interim analysis, Infinity is voluntarily stopping the trial. The company expects to present the final data after all analyses are complete.

BroadVision (Nasdaq: BVSN) 11.6% HIGHER; traders still buying today following a nearly 25 percent jump on Friday amid rumors of a Microsoft deal with Yammer.

KIT digital (Nasdaq: KITD) 11.3% LOWER; stock giving up gains from a late-day 11 percent move on Friday. Shares are now below support at $4.50.

DSW Inc. (NYSE: DSW) 10.9% LOWER; sees Q2 EPS of 60-64 cents, which compares to the Street estimate of 74 cents. Reiterated its FY12 outlook. Also announced the authorization of a $100 million stock repurchase program.

EnerNOC (Nasdaq: ENOC) 10.8% HIGHER; trading higher amid rumors of a potential bid for Elster.

Osiris Therapeutics (Nasdaq: OSIR) 10.6% HIGHER; continuing to hold above the 50-day simple moving average this week following a more than 40 percent run up last week. The sock had traded in a very tight range throughout the beginning of June.

A123 (Nasdaq: AONE) 10% HIGHER; traders buying the dip this week following extreme volatility last week. After jumping nearly 52 percent amid a rumor of a new "breakthrough" technology, the stock tumbled about 25 percent to close the week as analysts poo-pooed the rumor. Shares have pushed above the $1.20 level today and are now flirting with the $1.30 resistance/support level.




You May Also Be Interested In


Related Categories

Special Reports

Related Entities

Morning Movers, Stock Buyback, Earnings

Comments

Body
Tom on 2012-06-18 10:48:55
Mark as Spam | Reply to this comment

Body went below $10 for the first time since it went public.. It will go back above $10 after today's over reaction. Big Bucks for all buyint today and selling above $10


Add Your Comment